AI Health: The Engagement Metric Driving Investor ROI

The promise of artificial intelligence in healthcare hinges not just on diagnostic accuracy or predictive power, but fundamentally on its ability to integrate into clinical workflows and, critically, to foster sustained patient engagement. For investors, the ultimate leading indicator of digital health ROI isn’t just a cleared 510(k) or a robust data moat, but measurable improvements in member adherence and participation. This operational challenge, how to genuinely keep users engaged, is where AI truly differentiates itself.

The Foundation: Interoperability as the Engagement Enabler

Our expert consensus synthesis, derived from extensive interviews with executive leadership across leading digital health companies and venture capital firms, consistently highlights interoperability as the foundational enabler for superior member engagement. AI tools, no matter how sophisticated, cannot drive adherence if they operate in a silo, disconnected from the broader healthcare ecosystem. Seamless integration with Electronic Health Records (EHRs), existing provider workflows, and patient-facing applications is paramount. This integration reduces friction, automates communication, and contextualizes AI-driven insights, making them actionable and relevant to both providers and patients. Without this foundational layer, even the most innovative AI risks becoming a “zombie company,” unable to scale its impact or justify its valuation.

AI-Driven Personalization: Case Studies in Engagement

We’ve observed several AI-native companies that have successfully leveraged intelligent design and integration to significantly boost member engagement. These companies demonstrate that AI’s strength lies in its capacity for personalization and timely intervention, making healthcare more accessible and less burdensome for users.

Viz.ai: Streamlining Provider Engagement and Triage

While often viewed through the lens of acute care and diagnostic speed, Viz.ai’s success implicitly demonstrates how AI can enhance provider engagement, which in turn benefits patient outcomes and, by extension, member engagement within a health system. The platform’s ability to rapidly identify suspected strokes or pulmonary embolisms from imaging studies and immediately alert relevant care teams significantly reduces triage time. This AI-powered coordination ensures that patients receive critical interventions faster. For investors, this translates to improved clinical pathways, reduced length of stay, and better patient satisfaction scores. The efficiency gains fostered by such AI tools encourage greater adoption by clinical staff, creating a virtuous cycle where faster, more coordinated care leads to higher provider satisfaction and, ultimately, better patient experiences. The platform’s engagement metrics show a clear correlation between rapid alert deployment and subsequent clinical action, indicating a high level of trust and active use by clinicians Viz.ai case study on stroke triage improvement. Viz.ai has expanded its platform across multiple diseases and is now embedded in 2,000 hospitals, serving an estimated 230 million patients with more than 50 AI care pathways. The company also holds 13 FDA clearances and was the first to receive CMS reimbursement for AI software.

Eko Health: Empowering Clinical Adoption of Digital Stethoscopes

Eko Health exemplifies how AI can drive engagement in diagnostic tools by enhancing their utility and integrating them seamlessly into clinical practice. Their digital stethoscopes, augmented with AI for early detection of heart murmurs and other cardiac abnormalities, have seen high clinical adoption rates, with over 750,000 devices sold worldwide and 9 FDA clearances. The AI provides immediate, objective analysis, assisting clinicians in identifying subtle signs that might otherwise be missed. This augmentation doesn’t replace the clinician but empowers them, making their diagnostic process more efficient and accurate. For health systems, the AI-driven insights lead to earlier referrals and interventions, improving patient outcomes and reducing downstream costs. The high adoption rate of Eko’s technology among clinicians signals strong engagement, driven by the practical benefits and ease of integration into existing examination workflows Eko Health clinical adoption study. This widespread use by providers directly impacts patient care, leading to more thorough screenings and, by extension, more engaged patients who feel their conditions are being proactively managed.

Big Health: Sustaining Adherence in Digital Therapeutics

Big Health, a pioneer in digital therapeutics for mental health, offers a compelling example of AI’s role in sustained member engagement. Their platforms, like SleepioRx for insomnia and DaylightRx for anxiety, which are among nine FDA-cleared Digital Mental Health Treatments (DMHTs), deliver evidence-based cognitive behavioral therapy (CBT) through AI-driven personalized programs. Big Health recently secured $23.7 million in strategic funding to accelerate the adoption of these solutions. The challenge with digital therapeutics often lies in adherence, patients starting a program but not completing it. Big Health has tackled this by leveraging AI to personalize the user journey, adapt content based on user progress and feedback, and provide timely nudges and support. Their published clinical trial adherence data demonstrates significantly higher completion rates compared to traditional digital interventions, translating into measurable clinical improvements for users Big Health clinical trial adherence data. This sustained engagement is a critical signal for investors, as it directly correlates with therapeutic efficacy and, consequently, reimbursement potential and long-term value creation. The AI acts as a persistent, personalized coach, making the therapeutic journey manageable and motivating.

Investor Takeaways: Evaluating Engagement Metrics During Due Diligence

For investors and VCs performing due diligence on AI health companies, scrutinizing engagement metrics is non-negotiable. Look beyond headline user counts to delve into:

• Adherence Rates: For digital therapeutics, what percentage of users complete the full program? How does this compare to benchmarks for similar interventions?
• Feature Utilization: Are users actively engaging with core AI-powered features, or are they only using basic functionalities? Depth of engagement matters more than breadth.
• Clinical Workflow Integration: For provider-facing AI, how deeply is the tool embedded into daily clinical routines? Is it a “bolt-on acquisition” that adds friction, or a seamless enhancement that improves efficiency?
• Retention and Churn: Beyond initial engagement, what are the long-term retention rates? High churn can indicate a lack of sustained value, regardless of initial adoption.
• Feedback Loops: Does the company use AI to continuously learn from user behavior and feedback, iterating on the product to improve engagement over time? This speaks to a robust Predetermined Change Control Plan (PCCP) and commitment to GMLP principles.

Companies that can demonstrate a clear, data-driven narrative around sustained engagement, backed by strong clinical outcomes, are de-risked investments. They possess a competitive advantage, not just a patent thicket, because they have solved the fundamental human challenge of health behavior change.

Methodology Note: Expert Consensus Synthesis

This analysis is grounded in an expert consensus synthesis approach, drawing primarily from structured interviews with over 20 executives and senior partners across leading venture capital firms, health systems, and AI-native digital health companies. These interviews focused on practical challenges and successful strategies for implementing and scaling AI in healthcare, with a particular emphasis on metrics and drivers of user and provider engagement. Our findings synthesize recurring themes and validated approaches, providing a pragmatic framework for evaluating AI health vendors. The insights are further validated against peer-reviewed digital health engagement studies and clinical trial registries, ensuring a robust and authoritative perspective.